Pricing
Login
Home
Charts
Search
Watchlist
Products

Accretion Nutraveda Ltd

ANL
₹320.00-5.04%20 Nov 2026
Reports
Pharma Formulations

Accretion Nutraveda Ltd

ANL
₹320.00
-5.04%
20 Nov 2026
Ask AI
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
₹232Cr
Close
Close Price
₹320.00
Industry
Industry
Pharma Formulations
PE
Price To Earnings
28.93
PS
Price To Sales
4.73
Revenue
Revenue
₹49Cr
Rev Gr TTM
Revenue Growth TTM
96.63%
PAT Gr TTM
PAT Growth TTM
83.21%

Quarterly Results

Standalone
Numbers
Percentage
QuarterSep 2024Mar 2025Sep 2025Mar 2026Sep 2026
Revenue
RevenueCr
511142029
Growth YoY
Revenue Growth YoY%
173.080.1109.4
Expenses
ExpensesCr
48111623
Operating Profit
Operating ProfitCr
13346
OPM
OPM%
22.323.823.518.320.7
Other Income
Other IncomeCr
00000
Interest Expense
Interest ExpenseCr
00000
Depreciation
DepreciationCr
00000
PBT
PBTCr
12336
Tax
TaxCr
00111
PAT
PATCr
12235
Growth YoY
PAT Growth YoY%
198.756.4103.0
NPM
NPM%
15.215.816.613.816.1
EPS
EPS₹
16.04.74.74.56.5
QuarterSep 2024Mar 2025Sep 2025Mar 2026Sep 2026
Revenue
RevenueCr
511142029
Growth YoY
Revenue Growth YoY%
173.080.1109.4
Expenses
ExpensesCr
48111623
Operating Profit
Operating ProfitCr
13346
OPM
OPM%
22.323.823.518.320.7
Other Income
Other IncomeCr
00000
Interest Expense
Interest ExpenseCr
00000
Depreciation
DepreciationCr
00000
PBT
PBTCr
12336
Tax
TaxCr
00111
PAT
PATCr
12235
Growth YoY
PAT Growth YoY%
198.756.4103.0
NPM
NPM%
15.215.816.613.816.1
EPS
EPS₹
16.04.74.74.56.5

Profit & Loss

Standalone
Numbers
Percentage
Financial YearMar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
35163449
Growth
Revenue Growth%
72.4219.7110.096.6
Expenses
ExpensesCr
24122739
Operating Profit
Operating ProfitCr
114710
OPM
OPM%
21.424.423.320.519.7
Other Income
Other IncomeCr
00000
Interest Expense
Interest ExpenseCr
00011
Depreciation
DepreciationCr
00000
PBT
PBTCr
01369
Tax
TaxCr
00111
PAT
PATCr
01357
Growth
PAT Growth%
192.9204.3102.783.2
NPM
NPM%
9.716.415.615.115.2
EPS
EPS₹
7.822.86.99.311.1
Financial YearMar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
35163449
Growth
Revenue Growth%
72.4219.7110.096.6
Expenses
ExpensesCr
24122739
Operating Profit
Operating ProfitCr
114710
OPM
OPM%
21.424.423.320.519.7
Other Income
Other IncomeCr
00000
Interest Expense
Interest ExpenseCr
00011
Depreciation
DepreciationCr
00000
PBT
PBTCr
01369
Tax
TaxCr
00111
PAT
PATCr
01357
Growth
PAT Growth%
192.9204.3102.783.2
NPM
NPM%
9.716.415.615.115.2
EPS
EPS₹
7.822.86.99.311.1
Sales CAGR
1 Year110%
3 Years126%
5 Years-
TTM-
EBITDA CAGR
1 Year85%
3 Years123%
5 Years-
TTM-
PAT CAGR
1 Year103%
3 Years163%
5 Years-
TTM-
Avg. ROCE
1 Year17%
3 Years31%
5 Years-
TTM21%
CFO / EBITDA
1 Year-137%
3 Years-96%
5 Years-
TTM-

Balance Sheet

Standalone
Numbers
Percentage
Financial YearMar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
Equity CapitalCr
00077
Reserves
ReservesCr
0152833
Current Liabilities
Current LiabilitiesCr
2333
Non Current Liabilities
Non Current LiabilitiesCr
1124
Total Liabilities
Total LiabilitiesCr
45114250
Current Assets
Current AssetsCr
33930
Non Current Assets
Non Current AssetsCr
11212
Total Assets
Total AssetsCr
45114250
Financial YearMar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
Equity CapitalCr
00077
Reserves
ReservesCr
0152833
Current Liabilities
Current LiabilitiesCr
2333
Non Current Liabilities
Non Current LiabilitiesCr
1124
Total Liabilities
Total LiabilitiesCr
45114250
Current Assets
Current AssetsCr
33930
Non Current Assets
Non Current AssetsCr
11212
Total Assets
Total AssetsCr
45114250

Cash Flow

Standalone
Financial YearMar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
10-2-9
Investing Cash Flow
Investing Cash FlowCr
00-1-15
Financing Cash Flow
Financing Cash FlowCr
-10325
Net Cash Flow
Net Cash FlowCr
0001
Free Cash Flow
Free Cash FlowCr
10-3-15
CFO To PAT
CFO To PAT%
242.828.0-88.6-185.9
CFO To EBITDA
CFO To EBITDA%
109.618.8-59.5-136.7
Financial YearMar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
10-2-9
Investing Cash Flow
Investing Cash FlowCr
00-1-15
Financing Cash Flow
Financing Cash FlowCr
-10325
Net Cash Flow
Net Cash FlowCr
0001
Free Cash Flow
Free Cash FlowCr
10-3-15
CFO To PAT
CFO To PAT%
242.828.0-88.6-185.9
CFO To EBITDA
CFO To EBITDA%
109.618.8-59.5-136.7

Ratios

Standalone
Financial YearMar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
151232
Price To Earnings
Price To Earnings
29.728.9
Price To Sales
Price To Sales
4.54.7
Price To Book
Price To Book
4.26.5
EV To EBITDA
EV To EBITDA
21.0
Profitability Ratios
Profitability Ratios
GPM
GPM%
35.336.129.825.725.7
OPM
OPM%
21.424.423.320.519.7
NPM
NPM%
9.716.415.615.115.2
ROCE
ROCE%
21.435.439.417.020.6
ROE
ROE%
106.775.849.514.318.5
ROA
ROA%
6.917.723.712.114.8
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
151232
Price To Earnings
Price To Earnings
29.728.9
Price To Sales
Price To Sales
4.54.7
Price To Book
Price To Book
4.26.5
EV To EBITDA
EV To EBITDA
21.0
Profitability Ratios
Profitability Ratios
GPM
GPM%
35.336.129.825.725.7
OPM
OPM%
21.424.423.320.519.7
NPM
NPM%
9.716.415.615.115.2
ROCE
ROCE%
21.435.439.417.020.6
ROE
ROE%
106.775.849.514.318.5
ROA
ROA%
6.917.723.712.114.8
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Market CapitalizationMkt CapCr237233233232205202198
Close PriceClose₹150.0038.16404.00320.00167.10160.7067.20
IndustryIndustryPharma FormulationsPharma FormulationsPharma FormulationsPharma FormulationsPharma FormulationsPharma FormulationsPharma Formulations
Price To EarningsPE12.4020.4528.9320.600.282.72
Price To SalesPS1.065.752.294.732.433.122.51
RevenueRevenueCr2244110149846579
Revenue Growth TTMRev Gr TTM%26.7%-8.4%41.8%96.6%22.5%-14.9%
PAT Growth TTMPAT Gr TTM%43.3%-238.4%16.6%83.2%33.6%421.4%
Market CapitalizationMkt CapCr237233233232205202198
Close PriceClose₹150.0038.16404.00320.00167.10160.7067.20
IndustryIndustryPharma FormulationsPharma FormulationsPharma FormulationsPharma FormulationsPharma FormulationsPharma FormulationsPharma Formulations
Price To EarningsPE12.4020.4528.9320.600.282.72
Price To SalesPS1.065.752.294.732.433.122.51
RevenueRevenueCr2244110149846579
Revenue Growth TTMRev Gr TTM%26.7%-8.4%41.8%96.6%22.5%-14.9%
PAT Growth TTMPAT Gr TTM%43.3%-238.4%16.6%83.2%33.6%421.4%
Annual Reports
FY2026
Quarterly Reports
FY2026
Sep 26
ResultPPT
Transcript
Summary
Mar 26
Result
PPT
Transcript
Summary
Annual Reports
Quarterly Reports
Sep 26
ResultPPT
Transcript
Summary
Mar 26
Result
PPT
Transcript
Summary
Load More
Interviews